Status:
COMPLETED
Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma
Lead Sponsor:
Peking University People's Hospital
Collaborating Sponsors:
Peking University Shougang Hospital
Conditions:
Effect of Drug
Toxicity, Drug
Eligibility:
All Genders
3+ years
Phase:
NA
Brief Summary
Today, using a multi-modal approach consisting of preoperative (neoadjuvant) systemic polychemotherapy followed by local surgical therapy and then postoperative (adjuvant) chemotherapy, long-term, dis...
Eligibility Criteria
Inclusion
- histological diagnosis of osteosarcoma (confirmed by central pathological review by an expert pathologist from the Peking University People's Hospital)
- objective disease progression within 3 months prior to treatment according to RECIST 1.1
- previously treated with one to two lines of chemotherapy for metastatic disease
- have an adequate performance status (adults:Eastern Cooperative Oncology Group \[ECOG\] performance status of 0-1;children aged \>12 years: a score of ≥60% on the Karnofsky performance scale; children aged ≤12 years a score of ≥60% on the Lansky scale)
Exclusion
- a life expectancy of less than 3 months
- patients had to have adequate bone marrow function, normal renal function, normal liver function, and normal pancreatic function
- no other malignant tumors
- no malignant pleural and peritoneal effusion
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2021
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT04690231
Start Date
December 1 2020
End Date
June 1 2021
Last Update
March 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044